Filo Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
as on 19-12-2024
About Filo Lifesciences
The Corporate was formerly known as Filo Chemicals Private Limited. The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Leela Raju, Avinash Waghray, Anil Raju, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233TG2011PTC077327
- Company No.
077327
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2011
- Date of AGM
18 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Filo Lifesciences Private Limited offer?
Filo Lifesciences Private Limited offers a wide range of products and services, including Metal & Metal Made Products, Nano Powder, Bird Food, Poultry & Animal Food, Animal Feed Supplement, Fertilizers and Soil Additives, Fertilizer, Industrial Chemicals & Supplies, Disinfectant Chemicals.
Who are the key members and board of directors at Filo Lifesciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Avinash Waghray  | Director | 28-Jan-2013 | Current |
| Leela Raju | Director | 09-Nov-2011 | Current |
| Anil Raju | Director | 05-Dec-2013 | Current |
| Heramb Rahalkar | Director | 09-Apr-2018 | Current |
Financial Performance of Filo Lifesciences.
Filo Lifesciences Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Filo Lifesciences?
In 2017, Filo Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 09 Apr 2020 | ₹1.00 M | Open |
How Many Employees Work at Filo Lifesciences?
Unlock and access historical data on people associated with Filo Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Filo Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Filo Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
